Traces of bacteria inside brain tumors may affect tumor behavior
Researchers found bacterial genetic and cellular elements inside brain tumor cells that appear biologically active and may influence tumor progression and treatment outcomes
These bacterial elements were also found to be linked to specific immune and metabolic responses in brain tumors
Outcomes for glioma and other brain tumor patients remain poor, underscoring the need for better treatments, which these findings...
Americans have widespread misbeliefs about the cancer risks of alcohol, study finds
More than half of American adults misunderstand or underestimate the link between alcohol consumption and cancer ...
ESMO 2025: Oral drug demonstrates promising anti-tumor activity in patients with advanced lung cancer
Lung cancer is the leading cause of cancer-related death worldwide, with up to 4% of non-small cell lung cancer cases having a HER2 gene...
ESMO 2025: Targeted therapy plus radiation or surgery improves outcomes in patients with advanced lung cancer
Lung cancer is the leading cause of cancer-related death worldwide, with non-small cell lung cancer (NSCLC) the most common form
Approximately 15% of NSCLC patients have mutant EGFR, which drives cancer growth
Osimertinib blocks mutant EGFR, targeting against exon 19 deletion and L858R, the two most common EGFR mutations
Patients treated with osimertinib plus radiation or surgery did not...
Study reveals how bacteria in tumors drive treatment resistance in cancer
Researchers uncovered a previously unknown way for microbes within tumors to contribute to treatment resistance in certain cancers...
WCLC 2025: Combination therapy achieves durable response in advanced lung cancer patients
KRAS G12C mutations are among the most common drivers of non-small cell lung cancer (NSCLC), yet first-line targeted therapy options...
WCLC 2025: Bispecific antibody dose shows promising potential for extensive-stage SCLC
Pumitamig is a novel bispecific antibody targeting both the PD-L1 checkpoint and VEGF, a driver of angiogenesis, being studied in patients...
WCLC 2025: Brigatinib with local therapy can potentially improve outcomes for advanced NSCLC
Almost all patients with ALK-rearranged non-small cell lung cancer (NSCLC) end up with an incomplete response to targeted therapy with tyrosine...
WCLC 2025: Innovative ADC therapy shows promise in hard-to-treat small cell lung cancer
Small cell lung cancer (SCLC) remains one of the most aggressive and difficult-to-treat forms of lung cancer, with few effective therapies...